Santen Pharmaceutical Co., Ltd engages in the manufacture and sale of pharmaceutical products and medical devices. It operates through the following segments: Pharmaceuticals and Others. The Pharmaceuticals segment includes prescription ophthalmic drugs, anti-rheumatic pharmaceuticals, and over-the-counter products. The Others segment offers medical equipment and devices. The company was founded by Kenkichi Tagushi in 1890 and is headquartered in Osaka, Japan.

KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom.

Bio-Tree Systems, Inc. provides medical imaging application software solutions. It focuses on tracking and analyzing blood vessel trees, vascular networks, and other tubular networks with complex branching patterns in the human body. The company was founded by Raul A. Brauner and Joseph Mundy in 2003 and is headquartered in Framingham, MA.

RemeGen, Ltd. ("RemeGen") is a biopharmaceutical company in China dedicated to fulfilling unmet medical needs for patients with life-threatening conditions. RemeGen's main focus is research and development, manufacturing and commercialization of novel biologics, most notably monoclonal antibodies (mAb) and antibody-drug conjugates (ADCs). Headquartered in Yantai, Shandong Province, China, RemeGen has labs/offices in Beijing and California.

Board of Regents of The University of Oklahoma is a private company headquartered in Norman, OK, with domestic subsidiaries, specializing in radio broadcasting stations.

Zhen Health is committed to providing medical institutions with comprehensive technology solutions for ophthalmology clinical auxiliary diagnosis and treatment at home and abroad. They have a technical research and development team from first-line Internet companies, and have an ophthalmologist medical team to protect everyone's light, promote graded diagnosis, and precision medicine with artificial intelligence, big data, and cloud computing.

Fuzhou Yiying Health Technology Co., Ltd., established on 2018-05-03, Business scope includes health technology,medical technology,Computer hardware and software,Technology research and development of medical devices,Technology Promotion,technical consulting,Technical Services,technology transfer;Medical Research and Experimental Development;Health management information consultation;Undertake the design,make,acting,Publish various domestic advertisements;Conference and Exhibition Services;Data Processing and Storage Services;medical instruments,Wholesale of electronic products,Purchasing agency;Medical equipment rental and maintenance.

ZeaVision develops products for EyeCare Professionals and patients. ZeaVision's mission is to develop and market science-based supplements and vision care products to support healthy vision and prevent vision loss in the lives of many.

UAB Research Foundation (doing business as UABRF), a subsidiary of The University of Alabama System, is a company headquartered in Birmingham, AL. The firm engages in identify, assess, and market commercially viable technology developed at The University of Alabama at Birmingham.

The University of Iowa Research Foundation (UIRF) - a 501C3 corporation - commercializes University of Iowa developed technologies and inventions through licensing and new venture formation, and manages the subsequent revenue stream.

Johnson & Johnson Vision Care is committed to creating life-long solutions to vision care needs. Since the ACUVUE Brand made its debut in 1987 as the world’s first disposable soft contact lens, the company has repeatedly brought quality, scientific and innovative advancements to the industry. Headquartered in Jacksonville, Florida, the company has some 3,000 employees worldwide.

Japan Tobacco, Inc. engages in the manufacture and sale of tobacco, pharmaceutical and processed food products. It operates through the following divisions: Japanese Domestic Tobacco, International Tobacco, Pharmaceutical, and Processed Food. The Japanese Domestic segment deals with the production and sale of tobacco products in domestic areas. The International Tobacco segment manufactures and markets tobacco products worldwide. The Pharmaceutical segment develops, manufactures, and sells prescription drugs. The Processed Food segment offers processed food, bakery products and seasonings. The company was founded on April 1, 1985 and is headquartered in Tokyo, Japan.

Eisai R&D Management Co., Ltd., a subsidiary of Eisai Co., Ltd., is a company headquartered in Bunkyo, Japan. The firm engages in research and development of pharmaceuticals.

Sichuan Hesheng Vision Pharmaceutical Technology Development Co., Ltd., established on 2012-10-30, Business scope includes medical technology development,technical consulting(No pre-licensed items,Post-licensing projects operate on the basis of licenses or approval documents);Medical Research Services,Technical extension services(No pre-licensed items,Post-licensing projects operate on the basis of licenses or approval documents);Electronics and Information Technology,network technology,Computer software and hardware development;data processing;Health Advisory(Does not include health care activities);Conference Services;Sales of computer software and hardware;Computer Technology Services;Sales:medical instruments(Operate within the validity period within the scope approved by the Class II medical device operation filing certificate)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

Chengdu Yinhai Qiming Hospital Management Co., Ltd., established on 2015-12-09, Business scope includes business management consulting;Health Advisory(Does not include health care activities);medical technology,medical technology development,technical consulting(Does not include health care activities),technology transfer;Sales of medical devices(one type);Medical Research and Experimental Development;Electronics and Information Technology,Network technology development;Sales of computer software, hardware and auxiliary equipment;data processing;Conference Services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

Tsubota Laboratory, Inc. engages in research and development of pharmaceuticals and medical devices related to the treatment of myopia, dry eye, presbyopia, and related cases. The company was founded by Kazuo Tsubota on May 28, 2012 and is headquartered in Tokyo, Japan.

Neusoft Medical Systems Co., Ltd. engages in the research, development, manufacturing, and sale of large-scale medical diagnosis and treatment equipment and solutions as well as the provision of related services. Its products include computed tomography systems, magnetic resonance imaging systems, digital subtraction angiography systems, ultrasonic diagnostic equipment, positron emission tomography equipment, radiotherapy products, as well as in vitro diagnostic equipment and reagents. The company was founded on March 6, 1998 and is headquartered in Shenyang, China.

Retica Systems, Inc. is the only, full-eye biometric technology company. Retica offers the most advanced and accurate eye biometric authentication solutions for logical, physical and digital ID applications to government, industry and business enterprises worldwide. Led by David Muller PhD, an expert and successful entrepreneur in excimer laser technology, the Retica team of opthalmic scientists, IT engineers and entrepreneurs took a new approach to retinal biometric technology in 1999. Over the next six years, they employed new developments in opto-electronics and digital signal processing to create an unprecedented eye biometric system that successfully exploits the full potential of the eye into a four-phase solution that captures, collects, stores and identifies biometric information. As a transitional or augmented security option, the Retica system integrates iris information into a multi-modal solution that co-manages sequential, tightly-coupled retinal and iris data. Retica’s unique patented technology fuses together the images of the retina and the iris, thus significantly facilitating data collection and resulting in higher accuracy.

Acucela, Inc. operates as a clinical-stage biotechnology company. It discovers and develops novel therapeutics to treat and show the progression of sight-threatening ophthalmic diseases. Its pipeline includes drug candidates and therapeutics for the treatment of age related macular degeneration, cataracts, presbyopia, diabetic retinopathy, retinitis igmentosa and Stargardt disease. The company was founded by Ryo Kubota in April 2002 and is headquartered in Seattle, WA.